CCM
LVTX

CAAS Capital Management’s LAVA Therapeutics LVTX Stock Holding History

CAAS Capital Management’s Portfolio LVTX Stock Details LVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-30,000
Closed -$456K – 1176
2021
Q1 		$456K Buy
+30,000
New +$412K ﹤0.01% 953

Other funds holding LVTX

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.78B AUM 114.03% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

CAAS Capital Management's LVTX Position: Q2 2021 in Review

CAAS Capital Management sold out of LAVA Therapeutics (LVTX) in Q2 2021, closing a stake of 30,000 shares — an estimated $456K sold.

CAAS Capital Management first reported a position in LVTX in Q1 2021 and held it in 1 quarter. The position peaked at $456K in Q1 2021. 18 funds tracked by Wall St. Rank hold LVTX as of Q2 2021.

  • CAAS Capital Management reported no remaining LAVA Therapeutics position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 30,000 LAVA Therapeutics shares in Q2 2021, an estimated $456K.
  • CAAS Capital Management first reported a position in LAVA Therapeutics in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's LAVA Therapeutics position peaked at $456K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held LAVA Therapeutics as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.